KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $1.30 $2.47 Friday, 26th Apr 2024 AKBA stock ended at $1.34. This is 0.752% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 4.25% from a day low at $1.30 to a day high of $1.35.
90 days $1.30 $2.47
52 weeks $0.780 $2.47

Historical Akebia Therapeutics prices

Date Open High Low Close Volume
Apr 27, 2023 $0.83 $0.91 $0.80 $0.91 2 140 962
Apr 26, 2023 $0.712 $0.85 $0.682 $0.793 1 988 374
Apr 25, 2023 $0.650 $0.777 $0.650 $0.714 2 799 055
Apr 24, 2023 $0.650 $0.700 $0.650 $0.671 528 681
Apr 21, 2023 $0.630 $0.676 $0.590 $0.660 760 174
Apr 20, 2023 $0.706 $0.719 $0.654 $0.660 694 262
Apr 19, 2023 $0.662 $0.740 $0.660 $0.723 835 536
Apr 18, 2023 $0.659 $0.698 $0.633 $0.682 716 504
Apr 17, 2023 $0.627 $0.670 $0.610 $0.650 1 343 010
Apr 14, 2023 $0.624 $0.660 $0.601 $0.628 406 489
Apr 13, 2023 $0.623 $0.670 $0.623 $0.637 551 875
Apr 12, 2023 $0.660 $0.660 $0.600 $0.623 543 308
Apr 11, 2023 $0.548 $0.679 $0.548 $0.648 1 292 038
Apr 10, 2023 $0.540 $0.590 $0.532 $0.569 567 633
Apr 06, 2023 $0.516 $0.579 $0.506 $0.540 736 449
Apr 05, 2023 $0.539 $0.539 $0.490 $0.506 897 838
Apr 04, 2023 $0.582 $0.582 $0.521 $0.539 1 234 615
Apr 03, 2023 $0.574 $0.590 $0.530 $0.578 1 736 488
Mar 31, 2023 $0.570 $0.580 $0.542 $0.560 1 073 341
Mar 30, 2023 $0.600 $0.611 $0.551 $0.563 1 194 001
Mar 29, 2023 $0.600 $0.620 $0.550 $0.605 1 122 274
Mar 28, 2023 $0.640 $0.650 $0.588 $0.599 1 234 867
Mar 27, 2023 $0.620 $0.660 $0.611 $0.656 1 066 708
Mar 24, 2023 $0.690 $0.690 $0.613 $0.639 1 235 633
Mar 23, 2023 $0.670 $0.694 $0.620 $0.685 991 503
Click to get the best stock tips daily for free!

About Akebia Therapeutics

Akebia Therapeutics Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra... AKBA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT